STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024
STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types
Gene expression data shows upregulation of innate immunity pathways
Tumor regressions observed at all dose levels, 60-200 mg TIW
11 November 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it presented promising data from its Phase 1 clinical study evaluating its METTL3 RNA methyltransferase inhibitor, STC-15, at the Society of Immunotherapy for Cancer (SITC) 39th Annual Meeting, held in Houston, US, from 6-10 November 2024.
